Europe Sleep Apnea Devices Market Trends & Summary

The Europe Sleep Apnea Devices Market, valued at US$ 1.94 billion in 2024, is on track to reach US$ 3.77 billion by 2033, according to Renub Research. This impressive rise, supported by a CAGR of 7.68% between 2025 and 2033, reflects Europe’s growing need for advanced diagnostic and therapeutic solutions for sleep-related breathing disorders. With obstructive sleep apnea (OSA) affecting tens of millions of Europeans, technological innovation, expanding awareness, and robust healthcare infrastructure are shaping one of the region’s most dynamic med-tech segments.

This article explores the market outlook, growth drivers, segment analysis, and country-level insights, positioning Europe as a global leader in sleep apnea management and device adoption.

Download Free Sample Report

Understanding Europe’s Sleep Apnea Devices Market

Sleep apnea devices encompass a broad range of technologies designed to diagnose, monitor, and treat sleep apnea—particularly obstructive sleep apnea, where a narrowed or blocked airway repeatedly interrupts breathing during sleep. These devices include:

Therapeutic devices: CPAP, Auto-CPAP, BiPAP, Adaptive Servo-Ventilation

Diagnostic devices: Polysomnography (PSG), respiratory polygraphs, oximeters, actigraphy tools, and sleep screening devices

In Europe, sleep apnea is increasingly recognized not just as an isolated sleep disorder but as a major public health challenge linked to:

Hypertension

Stroke

Diabetes

Cardiovascular disease

Daytime fatigue and workplace accidents

Driven by lifestyle changes, obesity rates, and an aging demographic, sleep apnea device usage is surging across the continent in hospitals, sleep laboratories, and home settings. CPAP and BiPAP systems remain the dominant therapeutic choices, while advanced diagnostic tools and portable screening solutions continue to expand adoption.

Key Growth Drivers in the Europe Sleep Apnea Devices Market

1. Rising Prevalence of Sleep Apnea Across Europe

Sedentary lifestyles, rising obesity levels, and a rapidly aging population are fueling an alarming surge in sleep apnea cases across Europe. Studies estimate that 175 million adults—around 44% of Europe’s population—may have mild to severe sleep apnea, creating unprecedented demand for diagnostic and therapeutic solutions.

Country-level demographic trends further accelerate this need:

United Kingdom

The UK’s "Future of an Older Population" report notes that by 2040, nearly one in seven residents will be over 75.

Households led by individuals aged 85+ are projected to grow 161% by 2037.

The working-age population between 50 and retirement age will increase significantly, intensifying healthcare demands associated with aging—including sleep apnea management.

France

France’s elderly population is expected to rise from 15 million in 2012 to 24 million by 2060, ensuring long-term expansion for the sleep apnea device market.

The widespread acknowledgment of sleep apnea as a contributor to cardiac events, type 2 diabetes, and neurocognitive decline has prompted more individuals to seek testing and treatment, driving market growth.

2. Technological Advancements Transforming Sleep Apnea Management

Innovation remains at the heart of Europe’s fast-growing sleep apnea devices market. New devices are becoming:

Portable

Battery-efficient

Noise-reduced

Bluetooth-enabled

Equipped with cloud-based adherence monitoring

These next-generation features have significantly improved treatment compliance, long recognized as one of the biggest challenges in CPAP therapy.

A major technological development in late 2024 demonstrates Europe’s commitment to innovation:

🔹 December 2024 – Nyxoah SA launched its battery-free Genio neurostimulator in England, a breakthrough hypoglossal nerve stimulation system for OSA patients, now accessible through the NHS. This marks a major milestone in alternative therapies for CPAP-intolerant patients.

Advances in diagnostic equipment, including simplified home sleep testing kits and AI-powered analysis algorithms, are expanding early detection and enabling personalized therapy.

3. Strong Government Support & Reimbursement Policies

Government-led initiatives play a decisive role in Europe’s sleep apnea devices market expansion. Health systems across Germany, France, the UK, Italy, Spain, and the Nordics support both diagnosis and treatment through:

Public health campaigns

Insurance reimbursement for CPAP/BiPAP devices

Grants for establishing sleep labs

Public investment in telemedicine and remote monitoring

Additionally, the broader EU policy framework encourages technological independence and innovation:

🔹 Open Strategic Autonomy (OSA)—originally focused on defense and energy—is increasingly influencing health-related industries, strengthening Europe’s resilience and infrastructure in medical technology manufacturing and procurement.

This support enhances accessibility and speeds up patient adoption of both therapeutic and diagnostic devices.

Major Challenges in the Europe Sleep Apnea Devices Market

1. High Device Costs Impacting Adoption

Despite strong reimbursement frameworks, the high price of CPAP, BiPAP, and advanced diagnostic tools remains a barrier for many patients—particularly in Eastern Europe and economically weaker regions. Even with subsidies, out-of-pocket expenses deter treatment adherence, and significant cost differences persist between home and hospital-based care.

2. Underdiagnosis and Limited Awareness

Many Europeans still remain undiagnosed, especially in rural and underserved communities. Factors contributing to low detection include:

Limited sleep laboratories

Stigma around sleep disorders

Lack of trained sleep specialists

Minimal awareness of the health risks associated with untreated sleep apnea

This gap presents both a challenge and an opportunity for stakeholders aiming to expand market reach.

Segment Analysis: Europe Sleep Apnea Devices Market

Therapeutic Devices

CPAP Sleep Apnea Devices

The largest and most established segment. CPAP devices maintain continuous airflow to prevent airway collapse during sleep. Advances such as quiet motors, self-adjusting algorithms, and smart connectivity are boosting adoption, particularly in Germany and the UK.

Auto-CPAP Devices

Automatically adjust pressure levels based on real-time breathing patterns, improving comfort and compliance.

BiPAP Sleep Apnea Devices

Designed for patients who struggle with CPAP or those with comorbid respiratory conditions like COPD. Enhanced portability and multi-mode functionality are driving growth.

Adaptive Servo-Ventilation (ASV)

A premium solution targeting complex sleep apnea and central apnea, often used in clinical settings.

Diagnostic Devices

Polysomnography (PSG)

The gold standard for diagnosing OSA. Hospitals and sleep labs continue to invest heavily in modern PSG systems with AI-enabled scoring.

Oximeters

Low-cost, easy-to-use devices widely adopted for home monitoring and initial screening.

Actigraphy & Polygraph Systems

Portable diagnostic solutions that enable real-time monitoring and early detection, especially beneficial for remote areas.

Sleep Apnea Screening Devices

Growing rapidly as awareness increases and home testing becomes mainstream.

End-User Analysis

1. Sleep Laboratories, Clinics & Hospitals

These facilities remain primary centers for accurate diagnosis and device fitting. Public and private investment in sleep centers is boosting this segment.

2. Home Care Settings/Individuals

A rapidly expanding segment driven by portable devices, telehealth, and patient preference for comfortable, at-home treatment.

Country-Level Market Insights

United Kingdom

High awareness, robust reimbursement, and an aging population make the UK one of Europe’s strongest markets. Portable CPAP and AI-driven diagnostic tools are gaining rapid acceptance.

Germany

A technological powerhouse in medical devices, Germany leads in:

Smart sleep apnea device adoption

Remote monitoring capabilities

Hospital-based sleep disorder programs

In December 2024, Eli Lilly received FDA approval for Zepbound® (tirzepatide) for treating OSA with obesity, a development expected to influence European treatment pathways.

France

Strong reimbursement systems and nationwide awareness campaigns deliver consistent growth.

In July 2024, Inspire Medical Systems secured reimbursement approval for its breakthrough OSA therapy, reinforcing France’s commitment to innovative treatment.

Italy

Growing healthcare expenditure and increasing public recognition of sleep health are strengthening demand. Urban centers lead adoption of CPAP/BiPAP, while rural regions remain an expansion opportunity.

In December 2024, the European Medicines Agency expanded Mounjaro’s label to include potential sleep disorder treatment—another step forward in obesity-linked OSA management.

Key Players in the Europe Sleep Apnea Devices Market

Natus Medical Incorporated

ResMed Inc.

Somnomed

Apex Medical Corporation

Koninklijke Philips N.V.

Compumedics

Fisher & Paykel Healthcare

Nyxoah SA

These companies are shaping future developments through product innovation, research investments, and collaborations with European healthcare networks.

Final Thoughts

The Europe Sleep Apnea Devices Market is evolving rapidly as sleep health becomes a central pillar of preventive care. The combination of rising disease burden, aging populations, cutting-edge device innovations, and proactive government support positions Europe as a global leader in sleep apnea management.

However, challenges remain. Underdiagnosis, cost barriers, and limited rural access indicate that the next phase of growth will depend on affordability, awareness, and advanced, user-friendly home-care solutions.

As technology continues to transform how Europeans sleep, breathe, and live, the market’s future looks both promising and impactful—reshaping the continent’s sleep health landscape for years to come.